← EssilorLuxottica S. A. overview

EssilorLuxottica S. A. vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

EssilorLuxottica S. A. (EL.PA)

Q3 2026
▲3▼1

AI glasses boom lifts EssilorLuxottica, but privacy lawsuits and German complaint pose risks

  • AI glasses sales nearly double, driving Q2 growth EssilorLuxottica's AI-enabled glasses sales nearly doubled in Q2, helping revenue rise 7.2% to €7.7bn and net profit jump 12.9% to €1.6bn. This shows strong demand for the new product line, which is a key growth driver for the company.

    This is the main positive force behind the stock: booming demand for AI glasses directly boosts revenue and profit.

  • First-half profit rises, EPS up to €3.37 First-half net profit rose to €1.64bn from €1.45bn, with revenue up to €14.82bn and operating profit at €2.30bn. Earnings per share increased to €3.37 from €3.00, showing overall financial strength.

    Confirms the company's profitability and supports the stock's valuation.

  • German rights group files criminal complaint over smart glasses privacy HateAid filed a criminal complaint against Meta and Ray-Ban (EssilorLuxottica) over alleged data protection violations. The complaint could lead to legal scrutiny and potential restrictions, posing a regulatory risk to the smart glasses business.

    This is a real counterweight: regulatory and legal risks could hurt sales or lead to fines, affecting the stock.

  • Meta and EssilorLuxottica unveil new AI glasses lineup, expand markets At Meta Connect, the companies launched new models including camera-free audio glasses and third-gen Ray-Ban Meta, with over 100 styles by year-end. They are expanding into new markets and adding features like hearing enhancement, which should drive future sales.

    Shows ongoing product innovation and market expansion, key for future growth and investor confidence.

August 2026
▲3▼1

AI glasses boom lifts EssilorLuxottica, but privacy lawsuits and German complaint pose risks

  • AI glasses sales nearly double, driving Q2 growth EssilorLuxottica's AI-enabled glasses sales nearly doubled in Q2, helping revenue rise 7.2% to €7.7bn and net profit jump 12.9% to €1.6bn. This shows strong demand for the new product line, which is a key growth driver for the company.

    This is the main positive force behind the stock: booming demand for AI glasses directly boosts revenue and profit.

  • First-half profit rises, EPS up to €3.37 First-half net profit rose to €1.64bn from €1.45bn, with revenue up to €14.82bn and operating profit at €2.30bn. Earnings per share increased to €3.37 from €3.00, showing overall financial strength.

    Confirms the company's profitability and supports the stock's valuation.

  • German rights group files criminal complaint over smart glasses privacy HateAid filed a criminal complaint against Meta and Ray-Ban (EssilorLuxottica) over alleged data protection violations. The complaint could lead to legal scrutiny and potential restrictions, posing a regulatory risk to the smart glasses business.

    This is a real counterweight: regulatory and legal risks could hurt sales or lead to fines, affecting the stock.

  • Meta and EssilorLuxottica unveil new AI glasses lineup, expand markets At Meta Connect, the companies launched new models including camera-free audio glasses and third-gen Ray-Ban Meta, with over 100 styles by year-end. They are expanding into new markets and adding features like hearing enhancement, which should drive future sales.

    Shows ongoing product innovation and market expansion, key for future growth and investor confidence.

Latest
▲3▼1

AI glasses boom lifts EssilorLuxottica, but privacy lawsuits and German complaint pose risks

  • AI glasses sales nearly double, driving Q2 growth EssilorLuxottica's AI-enabled glasses sales nearly doubled in Q2, helping revenue rise 7.2% to €7.7bn and net profit jump 12.9% to €1.6bn. This shows strong demand for the new product line, which is a key growth driver for the company.

    This is the main positive force behind the stock: booming demand for AI glasses directly boosts revenue and profit.

  • First-half profit rises, EPS up to €3.37 First-half net profit rose to €1.64bn from €1.45bn, with revenue up to €14.82bn and operating profit at €2.30bn. Earnings per share increased to €3.37 from €3.00, showing overall financial strength.

    Confirms the company's profitability and supports the stock's valuation.

  • German rights group files criminal complaint over smart glasses privacy HateAid filed a criminal complaint against Meta and Ray-Ban (EssilorLuxottica) over alleged data protection violations. The complaint could lead to legal scrutiny and potential restrictions, posing a regulatory risk to the smart glasses business.

    This is a real counterweight: regulatory and legal risks could hurt sales or lead to fines, affecting the stock.

  • Meta and EssilorLuxottica unveil new AI glasses lineup, expand markets At Meta Connect, the companies launched new models including camera-free audio glasses and third-gen Ray-Ban Meta, with over 100 styles by year-end. They are expanding into new markets and adding features like hearing enhancement, which should drive future sales.

    Shows ongoing product innovation and market expansion, key for future growth and investor confidence.

Q2 2026
▲3

EssilorLuxottica expands AI glasses push and eyes Armani stake

  • Applied Materials partnership for AI glasses EssilorLuxottica signed a long-term deal with Applied Materials to develop advanced optical systems for AI and AR glasses. This gives the company access to cutting-edge display technology, strengthening its product pipeline and long-term growth prospects.

    This is a new strategic partnership that directly boosts EssilorLuxottica's technology and future product offerings.

  • Meta Glasses launch at $299 EssilorLuxottica and Meta launched a new line of AI-powered smart glasses starting at $299, making the technology more affordable. This broadens the customer base and could drive higher sales volumes for EssilorLuxottica as the manufacturing partner.

    A new product launch that expands the market for smart glasses and leverages EssilorLuxottica's partnership with Meta.

  • Potential Armani stake acquisition Giorgio Armani Group is preparing to sell a stake, with EssilorLuxottica named as a possible buyer. Buying a stake could give EssilorLuxottica a major luxury brand, boosting its portfolio and pricing power, though the process is still early.

    A potential acquisition that could significantly expand EssilorLuxottica's brand portfolio and market position.

June 2026
▲3

EssilorLuxottica expands AI glasses push and eyes Armani stake

  • Applied Materials partnership for AI glasses EssilorLuxottica signed a long-term deal with Applied Materials to develop advanced optical systems for AI and AR glasses. This gives the company access to cutting-edge display technology, strengthening its product pipeline and long-term growth prospects.

    This is a new strategic partnership that directly boosts EssilorLuxottica's technology and future product offerings.

  • Meta Glasses launch at $299 EssilorLuxottica and Meta launched a new line of AI-powered smart glasses starting at $299, making the technology more affordable. This broadens the customer base and could drive higher sales volumes for EssilorLuxottica as the manufacturing partner.

    A new product launch that expands the market for smart glasses and leverages EssilorLuxottica's partnership with Meta.

  • Potential Armani stake acquisition Giorgio Armani Group is preparing to sell a stake, with EssilorLuxottica named as a possible buyer. Buying a stake could give EssilorLuxottica a major luxury brand, boosting its portfolio and pricing power, though the process is still early.

    A potential acquisition that could significantly expand EssilorLuxottica's brand portfolio and market position.

▲3

EssilorLuxottica expands AI glasses push and eyes Armani stake

  • Applied Materials partnership for AI glasses EssilorLuxottica signed a long-term deal with Applied Materials to develop advanced optical systems for AI and AR glasses. This gives the company access to cutting-edge display technology, strengthening its product pipeline and long-term growth prospects.

    This is a new strategic partnership that directly boosts EssilorLuxottica's technology and future product offerings.

  • Meta Glasses launch at $299 EssilorLuxottica and Meta launched a new line of AI-powered smart glasses starting at $299, making the technology more affordable. This broadens the customer base and could drive higher sales volumes for EssilorLuxottica as the manufacturing partner.

    A new product launch that expands the market for smart glasses and leverages EssilorLuxottica's partnership with Meta.

  • Potential Armani stake acquisition Giorgio Armani Group is preparing to sell a stake, with EssilorLuxottica named as a possible buyer. Buying a stake could give EssilorLuxottica a major luxury brand, boosting its portfolio and pricing power, though the process is still early.

    A potential acquisition that could significantly expand EssilorLuxottica's brand portfolio and market position.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.